Prime Time News – 07/10/2020 – الكشف المبكر
حملة الكشف المبكر ومكافحة سرطان الثدي هذا الشهر
Related Articles
Over 40,000 housing units destroyed in 37 devastated southern Lebanese villages
Entire neighborhoods have been razed in 37 villages in southern Lebanon due to the intensification of Israeli bombardment and ground offensive, reported the National News…
Program Guide – ASCO Meeting Program Guide
Nagi S. El Saghir American University of Beirut Medical Center, Beirut, Lebanon Nagi S. El Saghir , Yoon Sim Yap , Yesim Eralp , Seock-Ah…
Best of ASCO Remains “The Best”: Celebrating 19 Years of Best of ASCO
For the 19th consecutive year, and despite war and economic collapse, we held our annual Best of ASCO meeting in Beirut, Lebanon, in July 2024.
On Graduating From Medical School: Reflections for My Son, Bassem,
As I celebrate this year’s medical school graduates, including my son, I hope they remember that hard work, perseverance, and good training build strong character.
On Graduating From Medical School: Reflections for My Son, Bassem,
As I celebrate this year’s medical school graduates, including my son, I hope they remember that hard work, perseverance, and good training build strong character.
Nagi El Saghir (@nagi_el_saghir) • Instagram reel
11 likes, 0 comments – nagi_el_saghir on July 12, 2024: “Welcome Opening ADVANCES IN CANCER THERAPY Best of #ASCO24 Lebanon july 2024 @aub_lebanon @aub_fm @aubmc_official…
Final results of RIGHT Choice: Ribociclib plus endocrine therapy vs combination chemotherapy in premenopausal women with clinically aggressive HR+/HER2− advanced breast cancer
PURPOSE: A head-to-head comparison of efficacy between a cyclin-dependent kinase 4/6 inhibitor plus endocrine therapy (ET) versus combination chemotherapy (CT) has never been reported in…
Final results of RIGHT Choice: Ribociclib plus endocrine therapy vs combination chemotherapy in premenopausal women with clinically aggressive HR+/HER2− advanced breast cancer
PURPOSE: A head-to-head comparison of efficacy between a cyclin-dependent kinase 4/6 inhibitor plus endocrine therapy (ET) versus combination chemotherapy (CT) has never been reported in…